Background
==========

Colorectal cancer (CRC) is the third most prevalent cancer and the fourth most common cause of cancer-related deaths worldwide, with approximately 1.4 million new diagnoses and nearly 700 000 deaths every year \[[@b1-medscimonit-26-e924448],[@b2-medscimonit-26-e924448]\]. In the typical CRC formation model, most cancers evolve from a polyp with abnormal crypt to early adenoma, then late adenoma, and finally to CRC \[[@b3-medscimonit-26-e924448]\]. Metastatic tumors that spread through the blood or lymphatic vessels might occur in most forms of human cancers. Regional lymph node metastasis (LNM), tumor-node-metastasis (TNM) stage, primary location, and molecular markers of the tumors are also regarded as important prognostic factors for CRC \[[@b4-medscimonit-26-e924448],[@b5-medscimonit-26-e924448]\]. Actually, most CRC develops through a series of histological, morphological, and genetic changes, which, accumulating over time, make it extremely important to screen and detect precancerous polyps before they become cancerous in individuals with an average risk of CRC \[[@b6-medscimonit-26-e924448]\]. The 5-year survival rate of CRC patients is 90% at stage I-II, 71% at stage III, and 14% at stage IV \[[@b7-medscimonit-26-e924448]\]. In addition, 40 to 50% of CRC patients develop metastatic disease, which hinders effective treatment and makes 5-year survival rate extremely low \[[@b8-medscimonit-26-e924448]\]. The dismal outcome of CRC has increased attention to the critical importance of early detection and novel therapeutic strategies.

As small membranous vesicles, extracellular vesicles (EVs) are found in blood, urine, and saliva, and can facilitate intercellular communication and affect the homeostasis of blood vessels by transporting microRNAs, long non-coding RNAs (lncRNAs), and mRNAs \[[@b9-medscimonit-26-e924448],[@b10-medscimonit-26-e924448]\]. Additionally, circulating EVs are abundant in serum, one of the most accessible sources \[[@b11-medscimonit-26-e924448]\]. EVs exert versatile functions in vascular biology, embryonic development, tissue repair, liver homeostasis, cancer progression, and immune and nervous system functioning \[[@b12-medscimonit-26-e924448]\]. Tumor-derived EVs, as new tumor biomarkers and functional regulators of tumor development, play pivotal roles in the interactions between tumor cells and immune cells in the tumor microenvironment, particularly in CRC \[[@b13-medscimonit-26-e924448]\]. In recent years, it has been recognized that lncRNAs stably exist in the blood and may mirror the physiological and pathological changes of cancer patients, which has aroused great interest in the possibility of using circulating lncRNAs as minimally invasive biomarkers for cancer detection \[[@b14-medscimonit-26-e924448]\]. Importantly, some circulating lncRNAs in serum EVs have been reported to differentially express in CRC patients and are therefore potential biomarkers for CRC diagnosis \[[@b15-medscimonit-26-e924448]\]. In light of this, we extracted serum EVs from CRC patients and healthy subjects. We then carried out microarray analysis to screen out the differentially expressed lncRNAs in serum EVs to determine the relationship between serum EV-derived lncRNA and their clinical significance in CRC.

Material and Methods
====================

Ethics statement
----------------

This study was approved and supervised by the ethics committee of Yantaishan Hospital. All procedures were strictly conducted as per the Code of Ethics. All patients signed informed consent.

Clinical sample collection
--------------------------

From January 2012 to June 2013, 94 CRC patients diagnosed and treated in Yantaishan Hospital were enrolled in this study, including 54 males and 40 females, with an average age of 59.22±9.64 years. All patients were followed up every 3 months for 5 years. The inclusion criteria were diagnosis with CRC by postoperative pathological examination; no treatment with radiotherapy or chemotherapy before surgery; and complete clinical data. Patients with chronic system diseases or other malignant tumors were excluded. During the same time, 41 healthy people who came to our hospital for physical examinations were selected as normal controls, including 27 males and 14 females, with an average age of 54.70±10.83 years. The diastolic and systolic blood pressures of the selected subjects were measured by sphygmomanometers, and 5 mL fasting venous blood was collected in the morning from each subject.

Isolation and identification of HMCs
------------------------------------

Blood samples from all subjects were coagulated at room temperature and centrifuged at 3000 g for 10 min. The serum was centrifuged at 4°C at 3000 g for 10 min and then at 4°C at 10 000 g for 30 min to remove cell debris. Then 1 mL of supernatant was centrifuged (Class H, R, and S preparatory ultracentrifuges; type 50.4 Ti Rotor; Beckman Coulter, Brea, CA, USA) at 4°C for 2 h to obtain the precipitate. The precipitates were washed with phosphate buffer saline (PBS), then filtered through a 0.22-μm millipore filter, and centrifuged at 4°C at 100 000 g for 2 h to precipitate the EVs. The EV precipitates were resuspended in 100 μL PBS to analyze EVs or in 100 μL lysate buffer (Beyotime Biotechnology Co., Ltd, Shanghai, China) for protein quantification. A DC protein assay kit (5000116, Bio-Rad, Inc., Hercules, CA, USA) was used for EV quantification. Western blot analysis was used to detect the EV marker proteins CD9, CD81, and CD63, and cis-Golgi matrix protein (GM130).

Microarray analysis
-------------------

Microarray analysis was performed following the steps described previously in the literature \[[@b16-medscimonit-26-e924448]\]. In brief, total RNA was extracted from the serum EVs from 6 CRC patients and 6 healthy subjects. Subsequently, total RNA from the EVs was extracted and 0.5 μg RNA was used for cDNA synthesis using a GeneChip 3′. *In vitro* transcription express kit (902789, Thermo Fisher Scientific, Waltham, MA, USA). Subsequently, the cDNA was segmented and hybridized with a human lncRNA expression array V3.0 (AS-LNC-H-V4.0, Arraystar Inc. Rockville, MD, USA). After hybridization, the microarray was washed and scanned with a GeneChip Scanner 3000 7G System (000213, Thermo Fisher Scientific).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------------------

Total RNA in serum was acquired using the RNAiso Plus and Trizol LS Reagent (both from Takara, Otsu, Shiga, Japan). Then, formaldehyde denaturation electrophoresis was used to verify high-quality RNA for subsequent experiments. RT-PCR was conducted as per the manufacturer's protocol using a PrimeScript RT reagent kit (Takara). Finally, the mRNA expression was quantified by standard real-time qPCR protocol via SYBR Premix Ex Taq (Takara) with glyceraldehyde-3-phosphate dehydrogenase as an internal reference. The primer sequences are shown in [Table 1](#t1-medscimonit-26-e924448){ref-type="table"}.

Measurement of CRC markers in serum
-----------------------------------

The levels of carcinoembryonic antigen (CEA), cancer antigen (CA)242, CA199 and CA153 in serum were determined by an immunoassay analyzer (Cobas E602, Roche Diagnostics, Indianapolis, Indiana, USA) in accordance with previous literature \[[@b17-medscimonit-26-e924448]\].

Statistical analysis
--------------------

Statistical analysis was conducted with SPSS21.0 (IBM Corp. Armonk, NY, USA). Kolmogorov-Smirnov test was used to determine whether the data were normally distributed. The measurement data were exhibited in mean±standard deviation. The *t* test was applied for comparisons between 2 groups, while one-way analysis of variance (ANOVA) and Tukey's multiple comparisons test were used for multi-groups. Pearson's correlation coefficient was used to test the correlation, and a receiver operating characteristic (ROC) curve was drawn to evaluate the predictive effects of serum EV-carried lncRNAs on CRC. A survival curve was drawn by the Kaplan-Meier method and analyzed by log rank test. The *P* value was obtained by a two-tailed test and *P*\<0.05 indicated statistical differences.

Results
=======

Clinical baseline characteristics of CRC patients
-------------------------------------------------

In our study, serum was harvested from 41 healthy subjects participating in physical examinations, including 27 males and 14 females, with an average age of 54.70±10.83 years. During the same period, 94 CRC patients were recruited, including 54 males and 40 females, with an average age of 59.22±9.64 years. There were no significant differences between the 2 groups in body mass index, age, and gender ([Table 2](#t2-medscimonit-26-e924448){ref-type="table"}). More detailed demographic data of the clinical samples are shown in [Supplementary Table 1](#s1-medscimonit-26-e924448){ref-type="supplementary-material"}.

Identification of serum EVs
---------------------------

EVs were extracted from the serum of the subjects by transmission electron microscope, nanoparticle tracking, and western blot analysis. The results showed that the size of extracted EVs was 104.3±6.94 nm, which accorded with the definition of small EVs in the revised edition of MISEV 2018 \[[@b18-medscimonit-26-e924448]\] ([Figure 1A--1C](#f1-medscimonit-26-e924448){ref-type="fig"}). Then, the protein content in the EVs was quantified using a DC protein assay kit, and the resulting content was 314.67±23.58 μg.

LncRNA XIST is highly expressed in serum EVs in CRC patients
------------------------------------------------------------

First, serum EVs from 6 CRC patients and 6 healthy subjects were analyzed by lncRNA microarray. With \|LogFC \>2\| and *P*\<0.05 as the screening criteria, 96 differentially expressed lncRNAs were screened out, 68 of which were upregulated, while 32 were downregulated. The heat map showed the first 30 differentially expressed lncRNAs ([Figure 2A](#f2-medscimonit-26-e924448){ref-type="fig"}). Then the first 6 significantly upregulated lncRNAs were detected by RT-qPCR, which was consistent with the microarray analysis ([Figure 2B](#f2-medscimonit-26-e924448){ref-type="fig"}). Subsequently, the diagnostic efficacy of lncRNA XIST, linc02037, linc01987, linc02041, TET2-AS1, and linc00174 to CRC was analyzed by an ROC curve, and the results showed that lncRNA XIST had the largest area under the curve (AUC) ([Figure 2C](#f2-medscimonit-26-e924448){ref-type="fig"}) (all *P*\<0.05), indicating lncRNA XIST had the best diagnostic efficacy.

High lncRNA XIST expression predicts worse prognosis
----------------------------------------------------

According to the lncRNA XIST expression in serum EVs, patients were assigned into a high expression group (\>6.4) or a low expression group (\<6.4), and Kaplan-Meier survival analysis was performed to evaluate the association between survival time and lncRNA XIST expression in serum EVs. The 5-year follow-up survey identified that patients with higher expression of lncRNA XIST (average life expectancy=34.26 months) in serum EVs had a worse 5-year survival rate and a shorter life cycle than those with lower expression of lncRNA XIST (average life expectancy=47.96 months) ([Figure 3](#f3-medscimonit-26-e924448){ref-type="fig"}) (*P*\<0.05).

LncRNA XIST expression is related to the malignant degree of CRC patients
-------------------------------------------------------------------------

To further analyze the relationship between lncRNA XIST expression in serum EVs and CRC, the expression profile of serum EV-carried lncRNA XIST in the 94 CRC patients with different TNM stages, LNM, and differentiation degree was assessed. It was revealed that CRC patients with higher expression of serum EV-carried lncRNA XIST had lower differentiation, higher LNM status, and TNM stage than those with lower lncRNA XIST expression (all *P*\<0.05) ([Figure 4A--4C](#f4-medscimonit-26-e924448){ref-type="fig"}).

Positive correlation between lncRNA XIST expression and serum indicators in CRC patients
----------------------------------------------------------------------------------------

To determine the diagnostic efficacy of serum EV-carried lncRNA XIST to CRC, CEA, CA242, CA199, and CA153, the marker contents in the serum of the 94 CRC patients were measured. Results of a Pearson correlation analysis showed that lncRNA XIST expression in serum EVs was positively correlated with CRC marker contents (all *P*\<0.05) ([Figure 5A--5D](#f5-medscimonit-26-e924448){ref-type="fig"}).

Discussion
==========

Although fecal occult blood testing and colonoscopy examination in the past decades has moderately increased the detection rate of early stage tumors, occult blood testing has relatively poor sensitivity, and colonoscopy is invasive and costly \[[@b14-medscimonit-26-e924448]\]. Meanwhile, many functional molecules are stably encapsulated in EVs, which are increasingly considered as promising biomarkers for cancer detection \[[@b19-medscimonit-26-e924448]\]. Also, biomarker candidates presented in EVs have been reported in pancreatic cancer and CRC \[[@b20-medscimonit-26-e924448],[@b21-medscimonit-26-e924448]\]. Based on this background, we aimed to search for novel CRC biomarkers in EVs from the serum of patients.

Many studies have revealed that XIST is highly expressed in CRC. For example, Chen et al. noticed that XIST was overexpressed in CRC cell lines and tissues, and high XIST expression was correlated with adverse overall survival (OS) in CRC patients \[[@b22-medscimonit-26-e924448]\]. Zhang et al. found high XIST expression was correlated with larger tumor size and higher TNM stages and predicted poor progression-free survival and OS of CRC patients \[[@b23-medscimonit-26-e924448]\]. To summarize, these researchers reached a consensus that lncRNA XIST is an oncogene in CRC and serves as a potential biomarker to predict prognosis in CRC patients. However, to the best of our knowledge, no studies have investigated the significant effects of serum EV-carried XIST in CRC until now. The present study showed that XIST in serum EVs in CRC patients was upregulated. Circulating EVs expressing tumor-specific proteins are potential biomarkers for various cancers \[[@b24-medscimonit-26-e924448]\]. Many clinical studies indicate that tumor-derived EVs and their contents have great potential as diagnostic tools for cancers \[[@b25-medscimonit-26-e924448],[@b26-medscimonit-26-e924448]\]. In addition, serum EVs from CRC patients were shown to promote cellular mobility and epithelial-mesenchymal transition \[[@b27-medscimonit-26-e924448]\]. CRC cell-derived EVs suppressed the proliferation of T cells and contributed to CRC progression \[[@b28-medscimonit-26-e924448]\]. Interestingly, a prior study demonstrated that circulating lncRNAs in serum/plasma EVs could serve as biomarkers for CRC diagnosis \[[@b15-medscimonit-26-e924448],[@b29-medscimonit-26-e924448]\]. Further, METTL14 inhibits proliferation and metastasis of CRC by downregulating oncogenic lncRNA XIST \[[@b30-medscimonit-26-e924448]\]. But there is little research investigating serum EV-carried XIST in CRC, which indicates, to some degree, the innovation of our study.

In any organ system, TNM staging, LNM, and distant metastasis detection are tricky problems for pathologists and clinicians \[[@b31-medscimonit-26-e924448]\]. By analyzing the relationship between XIST expression and CRC clinicopathological features, we found that CRC patients with higher XIST expression in serum EVs had a worse 5-year survival rate and shorter life cycle, lower differentiation, higher LNM status, and TNM stage than patients having lower XIST expression in serum EVs. From the results of their Kaplan-Meier survival analysis, Xiao et al. found that CRC patients with high serum XIST expression exhibited poor OS rates, chemoresponse, and recurrence-free survival rates, and thus identified XIST as an independent prognostic factor for CRC patients receiving 5-fluorouracil treatment \[[@b32-medscimonit-26-e924448]\]. Additionally, cancer cell-derived EVs activate fibroblasts, which degrade the extracellular matrix and induce oncogenic cytokines, contributing to further tumor metastasis and ultimately promoting cancer malignancy \[[@b9-medscimonit-26-e924448]\]. Several lncRNAs enriched in CRC cell-derived EVs are of prime significance in cancer progression and diagnosis \[[@b33-medscimonit-26-e924448]\]. Similarly, exosomal colorectal neoplasia differentially expressed-h in the serum of CRC patients was strongly correlated with LNM, distant metastasis, and OS rates, thus acting as a novel noninvasive serum-based biomarker for diagnosis and prognosis of CRC \[[@b34-medscimonit-26-e924448]\].

In addition, we assessed the correlation between XIST expression and the specific markers of CRC patients to explore their potential for prognostic prediction. Data supported that serum EV-carried XIST in CRC patients was positively correlated with CEA, CA242, CA199, and CA153 contents. Serum EVs of right-sided CRC may promote metastasis by upregulating extracellular matrix-related proteins, and thus potentially serve as diagnosis and prognosis biomarkers in CRC \[[@b27-medscimonit-26-e924448]\]. CEA is one of the most widely used and reliable blood CRC markers today \[[@b19-medscimonit-26-e924448]\]. CEA levels are correlated with the metastasis and recurrence of CRC after surgery \[[@b35-medscimonit-26-e924448],[@b36-medscimonit-26-e924448]\]. CA242 has high specificity and sensitivity in CRC patients, and the combination of CEA and CA242 is even more sensitive in CRC diagnosis \[[@b37-medscimonit-26-e924448]\]. The increased preoperative CA199 level indicates a low survival rate of CRC \[[@b38-medscimonit-26-e924448]\]. Increased CEA, CA199, and CA242 contents are associated with TNM stages and differentiation, and direct impact on metastasis, recurrence status, and survival time of CRC patients at stages II and III \[[@b37-medscimonit-26-e924448]\]. This is a preliminary finding and larger studies with proper testing and validation cohorts will allow for better understanding of the utility of this biomarker in CRC.

Conclusions
===========

Serum EV-transported lncRNA XIST has diagnostic and predictive effects on CRC. Preventing EV secretion by tumor cells or removing tumor cell-derived EVs is a potential therapeutic strategy worthy of further study. In addition, an in-depth understanding of the physiology of EVs during cancer development may pave the way for the design of diagnostic tools and therapeutic strategies for CRC. Further studies including large clinical samples and diverse ethnic populations are required to confirm the usefulness of lncRNAs as noninvasive markers in CRC patients.

Supplementary Data
==================

###### 

Demographic characteristics of the CRC patients.

  No.   Type   Stage   M   D        TS       Gender   Age   OS (months)   Status
  ----- ------ ------- --- -------- -------- -------- ----- ------------- --------
  1     CRC    I       Y   High     \<3 cm   Male     66    18            Dead
  2     CRC    II      N   Medium   \<3 cm   Female   51    24            Dead
  3     CRC    III     Y   Low      \>3 cm   Male     63    36            Dead
  4     CRC    IV      Y   Low      \<3 cm   Male     38    60            Live
  5     CRC    II      N   High     \<3 cm   Male     60    60            Live
  6     CRC    IV      Y   Low      \<3 cm   Female   53    30            Dead
  7     CRC    IV      N   Low      \<3 cm   Female   68    42            Dead
  8     CRC    II      Y   Low      \<3 cm   Male     52    39            Dead
  9     CRC    IV      N   Low      \<3 cm   Male     56    18            Dead
  10    CRC    IV      Y   High     \<3 cm   Female   62    12            Dead
  11    CRC    IV      Y   Low      \>3 cm   Female   66    18            Dead
  12    CRC    IV      Y   Low      \<3 cm   Male     71    15            Dead
  13    CRC    IV      Y   High     \>3 cm   Male     61    36            Dead
  14    CRC    IV      N   Low      \>3 cm   Male     71    42            Live
  15    CRC    IV      Y   Low      \<3 cm   Female   67    30            Dead
  16    CRC    III     Y   Low      \<3 cm   Female   66    39            Dead
  17    CRC    IV      N   Medium   \<3 cm   Male     66    33            Dead
  18    CRC    IV      Y   Medium   \<3 cm   Male     71    36            Dead
  19    CRC    IV      Y   Low      \>3 cm   Male     58    45            Live
  20    CRC    III     Y   Low      \<3 cm   Female   64    30            Dead
  21    CRC    IV      Y   Medium   \>3 cm   Female   58    15            Dead
  22    CRC    IV      Y   Medium   \<3 cm   Female   63    18            Dead
  23    CRC    IV      N   Low      \>3 cm   Female   72    33            Dead
  24    CRC    I       Y   Low      \>3 cm   Female   65    36            Dead
  25    CRC    IV      N   Low      \<3 cm   Male     60    60            Live
  26    CRC    IV      Y   Medium   \>3 cm   Male     60    24            Dead
  27    CRC    IV      N   Medium   \<3 cm   Male     61    24            Dead
  28    CRC    III     Y   Medium   \>3 cm   Female   66    33            Dead
  29    CRC    III     N   Medium   \>3 cm   Male     71    39            Dead
  30    CRC    II      Y   Medium   \<3 cm   Female   58    24            Dead
  31    CRC    III     Y   Low      \>3 cm   Male     66    60            Live
  32    CRC    III     N   Low      \<3 cm   Female   66    27            Dead
  33    CRC    IV      Y   Low      \>3 cm   Female   65    39            Dead
  34    CRC    IV      Y   Low      \>3 cm   Female   64    36            Dead
  35    CRC    III     N   Medium   \<3 cm   Male     73    39            Dead
  36    CRC    III     Y   Medium   \>3 cm   Female   73    27            Dead
  37    CRC    III     Y   Medium   \<3 cm   Female   66    45            Dead
  38    CRC    III     Y   Low      \>3 cm   Male     68    54            Dead
  39    CRC    III     N   Medium   \>3 cm   Female   67    30            Dead
  40    CRC    III     Y   Medium   \<3 cm   Male     63    60            Live
  41    CRC    III     Y   Medium   \<3 cm   Female   61    36            Dead
  42    CRC    III     Y   Low      \>3 cm   Male     67    18            Dead
  43    CRC    III     N   Medium   \>3 cm   Female   68    15            Dead
  44    CRC    II      Y   Medium   \<3 cm   Female   47    27            Dead
  45    CRC    III     Y   Medium   \<3 cm   Male     70    21            Dead
  46    CRC    II      Y   Medium   \>3 cm   Female   67    36            Dead
  47    CRC    III     Y   Medium   \>3 cm   Male     73    21            Dead
  48    CRC    III     Y   Low      \<3 cm   Male     40    39            Dead
  49    CRC    III     Y   Medium   \<3 cm   Female   55    54            Dead
  50    CRC    III     N   Medium   \>3 cm   Female   53    51            Live
  51    CRC    II      N   Low      \>3 cm   Male     45    30            Dead
  52    CRC    II      N   Medium   \>3 cm   Male     65    33            Dead
  53    CRC    II      N   Medium   \>3 cm   Male     39    18            Dead
  54    CRC    II      N   High     \>3 cm   Male     47    27            Dead
  55    CRC    II      Y   Medium   \>3 cm   Female   72    60            Live
  56    CRC    II      N   High     \>3 cm   Male     60    27            Live
  57    CRC    III     N   High     \<3 cm   Male     49    36            Dead
  58    CRC    II      N   High     \<3 cm   Male     54    33            Dead
  59    CRC    II      N   High     \<3 cm   Male     41    60            Live
  60    CRC    II      N   High     \>3 cm   Male     70    51            Dead
  61    CRC    II      Y   High     \>3 cm   Female   45    48            Dead
  62    CRC    II      N   Low      \<3 cm   Male     44    45            Dead
  63    CRC    II      N   Low      \<3 cm   Male     56    45            Dead
  64    CRC    II      N   Low      \<3 cm   Male     68    33            Dead
  65    CRC    II      Y   Low      \>3 cm   Female   62    39            Dead
  66    CRC    IV      N   High     \<3 cm   Female   47    27            Dead
  67    CRC    IV      N   High     \<3 cm   Female   43    60            Live
  68    CRC    II      N   High     \>3 cm   Male     54    60            Live
  69    CRC    III     N   Medium   \>3 cm   Male     62    60            Live
  70    CRC    II      N   Medium   \<3 cm   Male     65    33            Dead
  71    CRC    II      Y   High     \>3 cm   Male     43    45            Dead
  72    CRC    II      Y   High     \<3 cm   Male     50    48            Dead
  73    CRC    I       N   High     \>3 cm   Male     65    51            Live
  74    CRC    I       N   Low      \<3 cm   Male     67    54            Dead
  75    CRC    I       Y   High     \<3 cm   Male     45    57            Dead
  76    CRC    IV      N   High     \>3 cm   Female   60    51            Dead
  77    CRC    IV      N   High     \>3 cm   Male     51    60            Live
  78    CRC    I       N   Low      \>3 cm   Male     53    48            Dead
  79    CRC    I       N   High     \<3 cm   Male     58    60            Live
  80    CRC    I       Y   High     \>3 cm   Male     50    39            Dead
  81    CRC    III     N   High     \>3 cm   Female   68    27            Live
  82    CRC    I       Y   Low      \>3 cm   Female   53    36            Dead
  83    CRC    I       N   High     \<3 cm   Male     46    30            Live
  84    CRC    III     N   Low      \<3 cm   Male     68    42            Dead
  85    CRC    I       N   Low      \<3 cm   Male     41    30            Dead
  86    CRC    III     N   High     \<3 cm   Male     45    57            Dead
  87    CRC    III     N   Medium   \>3 cm   Female   64    42            Dead
  88    CRC    IV      N   Medium   \<3 cm   Male     73    42            Live
  89    CRC    I       N   High     \>3 cm   Male     43    39            Dead
  90    CRC    IV      Y   High     \<3 cm   Female   58    45            Dead
  91    CRC    I       N   Low      \>3 cm   Female   62    42            Dead
  92    CRC    III     N   High     \>3 cm   Male     47    33            Live
  93    CRC    I       Y   High     \>3 cm   Male     65    36            Dead
  94    CRC    I       N   High     \>3 cm   Female   68    30            Dead

M -- stands for metastasis; D -- stands for differentiation; TS -- stands for tumor size; CRC -- colorectal cancer.
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:   lymph node metastasis
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RT-qPCR
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:   tumor-node-metastasis
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![Identification of serum EVs. (**A**) Nanoparticle tracking analysis of serum EVs, represented as size *vs.* concentration. (**B**) Transmission electron microscope observed serum EVs. Scale bar=100 nm. (**C**) Representative immunoblots indicated that EVs isolated from blood serum of present enrichment of EVs markers CD9, CD81, and CD63 but do not contain Golgi matrix protein GM130, as detected by western blot analysis.](medscimonit-26-e924448-g001){#f1-medscimonit-26-e924448}

![Upregulation of lncRNA XIST in serum EVs in CRC patients. Microarray analysis of different expressed lncRNAs in serum EVs in 6 healthy participants and 6 CRC patients. (**A**) Heat map of 30 differentially expressed lncRNAs. (**B**) RT-qPCR was performed to determine lncRNA XIST, linc02037, linc01987, linc02041, TET2-AS1, and linc00174 expression in serum EVs in 41 healthy participants and 94 CRC patients. (**C**) ROC analysis for expression of lncRNA XIST, linc02037, linc01987, linc02041, TET2-AS1, and linc00174. For lncRNA XIST, areas under the ROC curve: 0.864; sensitivity: 88.3%; and specificity: 90.2%; for linc02037, areas under the ROC curve: 0.698; sensitivity: 56.4%; and specificity: 82.9%; for linc01987, areas under the ROC curve: 0.856; sensitivity: 92.6%; and specificity: 78.0%; for linc02041, areas under the ROC curve: 0.774; sensitivity: 61.7%; and specificity: 90.2%; for TET2-AS1, areas under the ROC curve: 0.828; sensitivity: 95.7%; and specificity: 70.7%; for linc174, areas under the ROC curve: 0.849; sensitivity: 85.1%; and specificity: 78.0%.](medscimonit-26-e924448-g002){#f2-medscimonit-26-e924448}

![Kaplan-Meier analysis was performed to overview the OS rate and median survival time among CRC patients allocated by median expression of serum EV-carried lncRNA XIST.](medscimonit-26-e924448-g003){#f3-medscimonit-26-e924448}

![Serum EV-carried lncRNA XIST is associated with CRC malignance. We analyzed the correlation between CRC patients' tumor differentiation level (**A**), LNM status (**B**) and TNM stage (**C**) with serum EV-carried lncRNA XIST expression. Each spot represents an individual's data. One-way ANOVA and Tukey's multiple comparison test were used for significance determination.](medscimonit-26-e924448-g004){#f4-medscimonit-26-e924448}

![Serum EV-carried lncRNA XIST level is associated with CRC serum biomarker. We analyzed the correlation between CRC patients' serum CEA content (r=0.806) (**A**), CA242 content (r=0.627) (**B**), CA199 content (r=0.254) (**C**), and CA242 content (r=0.706) (**D**) with serum EV-carried lncRNA XIST expression. Each spot represents an individual's data. Pearson correlation analysis was used for significance and co-relation determination.](medscimonit-26-e924448-g005){#f5-medscimonit-26-e924448}

###### 

Primer sequences of RT-qPCR.

  Sequence    Forward                   Reverse
  ----------- ------------------------- --------------------------
  XIST        CGCGGCGCCTGTGCGTGTGACA    AACUGGCCCUCAAAGUCCCGCU
  LINC02037   TCTATGAGGGCTTAGCTGCTTG    UAUGGCUUUCAUUCCUAUGUGA
  LINC01987   CCGCCGATCAGTGCACTACAGAA   CUGUGCGUGUGACAGCGGCUGA
  LINC02041   UCAGUGCACUACAGAACUUUGU    CCGCCGATCAGTGCACTACAGAA
  TET-AS1     CCGCCGAAACTGGCCCTCAAAGT   AACUGGCCCUCAAAGUCCCGCU
  LINC00174   CAUCAUCGUCUCAAAUGAGUCU    CGCGGCGCTATGGCTTTTCATTCC
  GAPDH       AUCUGGAGGUAAGAAGCACUUU    TCTATGATCTGGAGGTAAGAAG

RT-qPCR -- reverse transcription quantitative polymerase chain reaction; XIST -- X-inactive specific transcript; GAPDH -- glyceraldehyde-3-phosphate dehydrogenase.

###### 

Clinical baseline characteristics of CRC patients.

                  Healthy participants   CRC patients   *P* value
  --------------- ---------------------- -------------- -----------
  Age (years)     54.70±10.83            59.22±9.64     0.48
  Gender                                                0.20
  Male            27                     54             
  Female          14                     40             
  BMI (kg/m^2^)   23.65±3.36             21.86±2.88     0.22

CRC -- colorectal cancer; BMI -- body mass index.
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